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Abstract: The recommended treatment for metastatic urothelial carcinoma (mUC) patients is
platinum-based chemotherapy. Although initial response rates are moderate, the vast majority
of patients experience a relapse due to chemoresistance and eventually succumb to their disease.
Furthermore, platinum-based chemotherapy is toxic and approximately 30% of mUC patients are
unfit for chemotherapy. Thus, there is a clear unmet need for novel, more efficacious treatment
options in mUC with a safer toxicity profile. To propel the advancement of novel treatment options,
we present a summary of key signaling pathways and molecular mechanisms that are known to be
involved in bladder cancer tumorigenesis with a focus on promising candidate druggable molecular
targets and innovative targeted therapies currently under clinical investigation. Targetable alterations
were mainly described in fibroblast growth factor receptor (FGFR) and epidermal growth factor
receptor (ErbB) tyrosine kinase receptor (RTK) families, downstream pathways, and chromatin
remodelers, which are major bladder cancer driver genes. Drugs targeting the FGFR family members
are emerging as personalized treatment options for selected mUC patients with tumor-specific FGFR
alterations. The pan-FGFR inhibitor, erdafitinib, was first-in-class to receive U.S. Food and Drug
Administration (FDA) approval in 2019, while inhibitors of ErbB family members have shown
less potential. Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that deliver
cytotoxic drugs in close proximity to cancer cells by targeting RTKs or other transmembrane proteins.
Enfortumab vedotin is the first-in-class ADC that was FDA approved for the treatment of locally
advanced or mUC in 2019.
Keywords: muscle-invasive bladder cancer; tyrosine kinase receptor; RTK; targeted therapy;
personalized medicine
1. Introduction
Bladder cancer (BC) is a major source of morbidity and mortality, with an estimated 430,000 new
cases and 165,000 deaths in 2012 [1]. Tobacco smoke is the single most important risk factor associated
with BC [2]. Bladder cancer is almost always of urothelial origin, referred to as urothelial carcinoma
of the bladder. Three-quarters of BC patients have non-muscle invasive disease, which is treated by
transurethral tumor resection (TUR) followed by adjuvant intravesical instillations. Muscle-invasive
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bladder cancer (MIBC) is a life-threatening disease requiring aggressive treatment due to occult
micrometastasis. The recommended treatment option for non-metastatic MIBC is cisplatin-based
neoadjuvant chemotherapy (NAC) followed by surgical removal of the bladder (radical cystectomy).
In patients who want to keep their bladder, external beam radiotherapy together with concurrent
chemotherapy is a feasible alternative. Despite this extensive treatment, approximately half of the MIBC
patients who are treated with curative intent will progress to metastatic urothelial carcinoma (mUC).
The first-line treatment option in mUC is cisplatin-based chemotherapy, which includes combinations of
gemcitabine + cisplatin (gem/cis) or (dose-dense) methotrexate + vinblastine + doxorubicin + cisplatin
(ddMVAC), with associated objective response rates (ORRs) of 46% and 49%, respectively [3]. The
long-term survival benefits of gem/cis and ddMVAC regimens are equal, with a median survival
of 14 months [3]. Nonetheless, 30% of mUC patients are cisplatin-ineligible due to having a poor
performance status, renal dysfunction, or other comorbidities. Cisplatin-ineligible patients are treated
with carboplatin-containing chemotherapy, which has a lower anti-cancer effect but a more favorable
toxicity profile than cisplatin [4]. In recent years, immune checkpoint inhibition (ICI) has shown its
superior efficacy in mUC patients that relapsed after platinum-based therapy (platinum-relapsed)
compared to second-line chemotherapy [5]. The U.S. Food and Drug Administration (FDA)-approved
second-line treatment options pembrolizumab or atezolizumab, for treatment of mUC patients, which
were associated with ORRs of ~20% [5,6]. Although the response rates to ICI are low and the median
overall survival benefit for all-comers is limited, it is important to emphasize that the majority of
responses to ICI are durable, with a median duration of response to atezolizumab of 16 months,
while 68% of responses to pembrolizumab lasted over 12 months [5,6]. For mUC patients that
experience a relapse after ICI, no standard treatment options are available. Recent gene expression
studies of MIBC identified six molecular subtypes but novel candidates for targeted therapies were
not found. These MIBC molecular subtypes are luminal papillary (24%), luminal nonspecified
(8%), luminal unstable (15%), stroma-rich (15%), basal/squamous (35%), and neuro-endocrine-like
(3%) [7]. The Cancer Genome Atlas (TCGA) project showed that approximately 69% of MIBC patients
harbored molecular alterations that could be targeted for therapy [8–10]. The multiomics approach of
TCGA combined gene-expression profiling with whole-exome sequencing, RPPA protein expression,
and DNA methylation that culminated into a snapshot of the molecular landscape of MIBC [8–10].
Frequently occurring alterations were identified in the receptor tyrosine kinase (RTK)/MAPK pathway,
(RTK)/PI3K/AKT/mTOR pathway, and chromatin-modifying genes. Identification of BC driver genes
provides an opportunity to develop and investigate personalized treatment options for UC, and as
a result, the study of mUC is rapidly evolving. Recently, the FDA has granted accelerated approval
for erdafitinib, a first-in-class pan-FGFR (fibroblast growth factor receptor inhibitor, and enfortumab
vedotin, a first-in-class antibody-drug conjugate (ADC). The aim of this review was to provide a
contemporary overview of targeted therapy in mUC. We address clinical trials that are currently being
conducted in mUC patients and highlight future promising candidates for novel treatment options.
2. Methods
A literature search was conducted using the Embase, Medline, Web of Science Core Collection,
Cochrane Central Register of Controlled Trials, and Google Scholar databases for results on urothelial
cancer and tyrosine kinase inhibitors published from 1988 until March 2020. The Embase search was
as follows: “(‘bladder cancer’/exp OR ‘transitional cell carcinoma’/de OR ‘ureter carcinoma’/de OR
(((bladder* OR transition*-cell* OR urothelial OR ureter* OR uretal) NEAR/3 (cancer* OR neoplas*
OR malign* OR carcinom* OR metast* OR tumor* OR tumour*))):ab,ti,kw) AND (‘protein tyrosine
kinase inhibitor’/exp OR ‘epidermal growth factor receptor kinase inhibitor’/exp OR (((tyrosin* OR
epidermal-growth* OR EGF) NEAR/3 (kinas*) NEAR/3 (inhibitor*))”. The search resulted in 4888
full-text articles and/or congress papers published in the English language, including 1293 duplicates.
After the removal of duplicates, 3595 results were screened by title and abstract. Eventually, 591 studies
were grouped according to pre-determined subjects: (1) FGFR family, (2) epidermal growth factor
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receptor (ErbB) family, (3) MAPK pathway, (4) PI3K pathway, and (5) unspecified. However, 512 of the
selected publications proved irrelevant and were excluded upon assessment of the full-text articles
because of low-level evidence (case series, expert opinions, comments on other articles), or because
congress papers and interim analysis became outdated when studies were published as primary
research articles. Ultimately, 79 articles were included in this review.
3. Pharmacological Inhibition of Fibroblast Growth Factor Receptor Signaling
RTKs and their downstream signaling pathway members are frequently mutated in treatment-naive
MIBC [8–10]. Whole-exome sequencing of 131 MIBC patients identified molecular alterations in the
RTK/MAPK pathway in 45% of cases and the PI3K/AKT/mTOR pathway in 42% of cases [8–10].
Both MAPK and PI3K/AKT/mTOR pathways can be activated by the same RTKs, as illustrated in
Figure 1 [11]. RTKs contain an extracellular ligand-binding domain, a transmembrane domain, and an
intracellular tyrosine-kinase domain. Ligand binding causes RTKs to dimerize and become activated.
Constitutively activated RTK signaling can occur in the presence of missense mutations, gene fusions,
and increased RTK protein expression through altered gene expression or gene amplifications. RTKs
involved in UC are primarily members of the FGFR family (FGFR1, FGFR2, FGFR3, and FGFR4) and
members of the ErbB receptor family [8–10].
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Figure 1. Therapeutic targets in muscle-invasive bladder cancer (MIBC). Schematic overview of
(RTK)/MAPK (blue) and (RTK)/PI3K/AKT/mTOR (yellow) pathway alterations that are frequently
detected in MIBC patients. Gene alteration frequencies are indicated as percentages under the
corresponding proteins. Therapeutic agents that target particular or multiple RTKs are shown above
their corresponding targets. Therapeutic agents targeting PIK3CA or mTOR (orange) are depicted next
to their targets.
Approximately 11–12% of MIBC patients undergoing a cystectomy have activated FGFR3
mutations [8,12]. Of these mutations, 95% are in the extracellular or transmembrane domain and result
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in an amino acid changing into a cysteine. This causes the formation of disulfide bridges between two
receptor molecules and the constitutive activation of the receptors [13]. FGFR3-activating mutations
were detected in 8/27 superficial tumor areas from patients with MIBC, yet only 4 of these 8 mutations
were also present in the muscle-invasive front [12]. In addition, 5% of the lymph node metastases
contained FGFR3 mutations matching those detected in the primary tumor [12]. Future studies
should include multiple samples from papillary (superficial) and invasive tumor areas to confirm
initial findings that imply a decline in FGFR3 mutation frequencies as tumors progress. Nonetheless,
the corresponding FGFR3 mutations between primary MIBC tumors and lymph node metastases
provide a rationale for systemic FGFR3-directed therapy.
In addition to FGFR3 mutations, 30–40% of patients with MIBC have FGFR3 overexpression [14,15].
However, FGFR3 overexpression has no effect on clinical outcome in MIBC patients treated with
radical cystectomy [16]. FGFR3 gene amplifications (3%) and FGFR3 gene fusions (2%) are rare events
in MIBC [8–10].
FGFR1 amplifications are the most frequently detected FGFR1 alterations and are reported
in 7% of UC patients [17]. In addition to gene amplifications, alternative splicing of FGFR1 is
associated with increased tumor stage and grade [18]. Interestingly, FGFR1 overexpression induced
epithelial-to-mesenchymal transition (EMT) in UC cell lines [19,20]. FGFR2 gene fusions have been
described in 2–3% of BC patients [17]. Thus, molecular alterations in FGFR1, FGFR2, and FGFR3 have
been described as cancer driver genes in mUC. Patient tumors can simultaneously harbor multiple
FGFR alterations [8–10]. In addition, tumor cells can upregulate one FGFR in response to inhibition of
another. The presence of multiple synchronous FGFR-alterations and resistance mechanisms provide
a rationale for combined inhibition of FGFR1, FGFR2, and FGFR3. Recently, several therapeutic
agents targeting multiple FGFRs have been investigated (Table 1). Infigratinib (BGJ-398) is an FGFR1-3
inhibitor with response rates of 40–50% in metastatic upper tract urothelial carcinoma (UTUC) patients
with FGFR3 mutations or fusions [21,22]. Adjuvant treatment of MIBC/UTUC with infigratinib
is currently under investigation in the phase III PROOF 302 trial (NCT04197986). AZD4547 is an
inhibitor of FGFR1/2/3, tyrosine-protein kinase KIT (c-KIT), and colony-stimulating factor 1 receptor
(CSF1R) with weaker activity against FGFR4 [23]. AZD4547 is currently being investigated in the
BISCAY trial (NCT02546661) as part of a biomarker-directed, multidrug phase Ib open-label trial for
treatment-relapsed mUC patients. AZD4547 treatment is also examined in the biomarker-directed
MATCH Screening Trial (NCT02465060), which is a basket trial including mUC patients. Patients
harboring somatic FGFR1-3 mutations or translocations, determined by DNA sequencing of tumor
biopsies, will receive AZD4547 treatment until disease progression or unacceptable toxicity occurs.
Rogaratinib (BAY1163877) is an FGFR1–4 inhibitor that was found to be well tolerated in a phase I/II
clinical trial [24]. Rogaratinib is currently under investigation as a second-line treatment in patients
with locally advanced or mUC expressing FGFR1/3 mRNA, identified by in situ hybridization of
archival tissue, in the FORT-1 trial (NCT03410693). Derazantinib is a selective FGFR2 inhibitor that is
being investigated as a single treatment or in combination with atezolizumab as a first- or second-line
treatment in the FIDES-02 trial, which enrolled an estimated 303 patients with mUC harboring genetic
FGFR aberrations (NCT04045613). Erdafitinib, a pan-FGFR inhibitor, showed promising results due to
its limited toxicity, an overall response rate (ORR) of 40%, and a complete response rate (CR) of 3% in
mUC patients with FGFR3 alterations [25]. Based on these results, erdafitinib was granted accelerated
FDA approval as a second-line treatment for mUC patients with FGFR alterations. Nonetheless,
it remains to be determined whether mUC patients with FGFR1 or FGFR3 overexpression or alternative
splicing of FGFR1 benefit from FGFR inhibitors.
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Table 1. Targeted therapies that are currently being investigated in MIBC.
Drug Target Clinical Trials
erdafitinib FGFR1–4 NCT03473743, NCT02465060 (MATCH)
infigratinib (BGJ-398) FGFR1–3 NCT04197986 (PROOF 302),
AZD4547 FGFR1–4, Kit, CSF1R NCT02546661 (BISCAY), NCT02465060(MATCH)
rogaratinib (BAY 1163877) FGFR1–4 NCT03410693 (FORT-1)
derazantinib (ARQ 087) FGFR2 NCT04045613 (FIDES-02)
afatinib (BIBW2992) ErbB1–4 NCT02780687 (LUX Bladder-1)
trastuzumab deruxtecan (DS-8201a) Erbb2 NCT03523572
cabozantinib (XL184) VEGFR, c-MET, AXL, RET NCT01688999, NCT03866382, NCT03824691(ARCADIA), NCT03170960 (COSMIC-021)
copanlisib mTOR NCT02465060 (MATCH)
GSK2636771 mTOR NCT02465060 (MATCH)
valemetostat (DS3201) EZH2 NCT04388852
tazemetostat (EPZ-6438) EZH2 NCT03854474
rucaparib PARP1 NCT03397394 (ATLAS)
olaparib PARP1 NCT03375307, NCT02546661 (BISCAY)
entinostat HDAC I NCT03978624
ARCADIA: (hARnessing CAbozantinib and Durvalumab Immuno-oncology Association, c-MET: MET
proto-oncogene, CSF1R: Colony stimulating factor 1 receptor, ErbB: epidermal growth factor receptor, EZH2:
Enhancer of zeste homolog 2, FGFR: fibroblast growth factor receptor, HDAC1: Histone deacetylase 1, MATCH:
Molecular Analysis for Therapy Choice, mTOR: mammalian target of rapamycin, PARP: Poly(ADP-ribose)
polymerase 1 RET: Ret proto-oncogene, VEGFR: vascular endothelial growth factor receptor.
4. Targetting ErbB Receptor Family Signaling
The ErbB family consists of four RTKs: epidermal growth factor receptor (EGFR, also called HER-1
or ErbB-1), HER2 (also called ErbB-2 or HER-2/Neu), HER3 (ErbB3), and HER4 (ErbB4) [26]. Of these,
EGFR and HER-2 have been implicated in BC.
EGFR gene amplifications have been described in 9–14% of MIBC cases [9,27]. EGFR expression
is enriched in the basal/squamous subtype [7,27]. Likewise, the activity of the EGFR regulon is also
increased in basal/squamous tumors [7,28]. The basal/squamous expression subtype is a major MIBC
subtype, found in approximately 35% of MIBC patients and is associated with poor outcome after
radical cystectomy [7]. Despite upregulated EGFR mRNA expression and increased activity of the
EGFR regulon in basal/squamous MIBC, the EGFR targeting antibody cetuximab did not show any
additional benefit over gem/cis in patients with mUC, irrespective of the EGFR status [29].
HER2 is amplified or mutated in 9% of MIBC cases [8–10,30]. A study of 90 MIBC patients treated
with cystectomy showed that HER2 overexpression detected using immunohistochemistry (IHC)
was associated with a lower recurrence-free and cancer-specific survival [31]. In contrast, a larger
study that compared two primary tumor samples with two matched lymph node metastasis from 137
patients using fluorescence in situ hybridization (FISH) and IHC could not confirm these findings;
while HER2 amplifications in primary tumors were associated with lower overall survival, there
was poor concordance between the HER2 gene amplifications (using FISH) and protein expression
(using IHC) [30]. Interestingly, a higher frequency of HER2 amplifications was described in lymph
node metastases compared to primary MIBC tumor samples (15.3% vs. 8.7%) [30]. Thus, while HER2
amplifications seem to be associated with a poor prognosis and more frequent tumor progression,
the prognostic implications of HER2 overexpression are currently unclear. Both HER2 amplification
and overexpression are well-validated biomarkers for anti-HER2 targeted therapy in breast and gastric
cancers but clinical trials investigating HER2 inhibition in MIBC patients with HER2 or EGFR alterations
have not been promising. Treatment with lapatinib, an EGFR/HER2 specific small-molecule inhibitor,
showed no efficacy over that of a placebo in a phase III trial in mUC patients with positive EGFR and
HER2 expression [32]. Furthermore, HER2 inhibition with the monoclonal antibody trastuzumab in
conjunction with gem/cis or gemcitabine and carboplatin (gem/carbo) did not yield additional clinical
benefit in mUC patients with HER2 overexpression, compared to chemotherapy alone [33].
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Biological differences between MIBC and breast cancer might provide an explanation why
HER2-targeted therapy has not been as successful in MIBC as in breast cancer. Differences in response
to HER2-targeted therapy observed between breast cancer and mUC patients might be explained by
dissimilar HER-2 mutations driving tumor growth. HER2 alterations are equally found in TCGA
MIBC and breast cancer datasets, although MIBC is characterized by more point mutations and
fewer gene amplifications [9]. Putative activating mutations in the extracellular domain of HER2 are
described as being present in 40% of the histological variant micropapillary UC compared to 5–9%
of non-micropapillary UC [34,35]. Micropapillary disease is a rare histological subtype present in
around 2% of MIBC patients and is associated with a poor prognosis [36]. The association between
putative HER2 activating mutations, worse prognosis and a particular histological variant suggests
driver effects of putative HER2 activating mutations. On the other hand, HER2 amplifications are most
frequently detected in the MIBC subtype identified as “genomically unstable” [27]. This subtype is
associated with worse prognoses and is characterized by frequent chromosomal aberrations that can
lead to copy-number alterations (CNAs). Due to frequent CNAs detected in this subtype, it has been
hypothesized that HER2 amplifications, in the presence of many other large chromosomal aberrations,
are possibly passenger effects in MIBC [37]. Thus, patient selection based on HER2 amplifications or
IHC alone might not be the best method for selecting MIBC patients for HER2-targeted therapy [27,37].
Currently, the LUX Bladder-1 trial is investigating monotherapy with the ERB1-4 inhibitor afatinib in
platinum-relapsed mUC patients with either HER2 or HER3 mutations, HER2 amplifications, or EGFR
amplifications (NCT02780687).
In summary, HER2 and EGFR inhibitory therapy have been evaluated in MIBC with initially
disappointing results, which was potentially due to an inadequate patient selection process that focused
on HER2 amplifications and/or overexpression instead of activating mutations. Future studies on the
targetability of HER2 and EGFR should not neglect the molecular landscape of MIBC, which suggests
that patient selection should be based on activated HER2 mutations (micropapillary variant histology)
and HER2 or EGFR regulon activity as interesting candidates for ErbB inhibitory therapy.
5. MAPK and Pi3K/AKT/mTOR Pathway Alterations
The MAPK and Pi3K/AKT/mTOR signaling cascades are activated by RTKs. Activation of MAPK
and PI3K signaling cascades is a common finding in BC and promotes cell growth and survival [38].
These pathways show frequent crosstalk by sharing subunits and negative/positive feedback loops [38].
Activating mutations in RAS genes—HRAS (5%), KRAS (5%), or NRAS (2%)—are present in a minority
of MIBC patients [9]. The Pi3K/Akt/mTOR pathway can also be directly activated by activating
mutations in the phosphoinositide 3-kinase catalytic subunit alpha (PIK3CA). Constitutively active
PIK3CA produces phosphatidylinositol-3-phosphate (PIP3), which activates downstream actors of
the Pi3K/Akt/mTOR pathway. Approximately 22% of MIBC patients have such activating PIK3CA
mutations [8]. Other genes commonly mutated in the Pi3K/AKT/mTOR pathway are the tumor
suppressor genes PTEN and TSC1. PTEN is a phosphatase that antagonizes Pi3K by breaking down
PIP3 and is mutated in 3% of MIBC patients, while TSC1 inhibits the pathway further downstream and
is mutated in 8% of MIBC patients [8]. The MAPK and Pi3K/AKT/mTOR pathways are interesting
candidates for targeted therapy, as more than 25% of patients have alterations in one of these pathways.
However, crosstalk between the MAPK and Pi3K/AKT/mTOR pathways and upstream RTKs provide
cancer cells with effective mechanisms to escape treatment directed against one pathway via activation
of the other [38–43]. For example, cell lines upregulate EGFR expression to overcome a temporary
decrease in MAPK signaling induced by FGFR inhibition [41]. In addition, downstream activation of the
Pi3K/AKT/mTOR pathway has been described as a resistance mechanism to FGFR inhibition [40,42,43].
Thus, these findings prompt development of a method that produces a combined inhibition of the
RTK-MAPK and RTK-Pi3K/AKT/mTOR pathways.
A phase I study investigating the mTOR inhibitor everolimus combined with the vascular
endothelial growth factor RTK (VEGFR) inhibitor pazopanib showed a favorable toxicity profile and
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clinical benefit was observed in 4 of 19 included patients with mUC harboring TSC1/TSC2 mutations [44].
Two PIK3CA inhibitors are also included in the MATCH basket trial: copanlisib (BAY 80-6946) for
patients with Pi3KCA-activating mutations and or PTEN-inactivating mutations, and GSK2636771
for patients with PTEN-inactivating mutations (NCT02465060). The mTOR inhibitor sorafenib was
investigated in the neoadjuvant setting in combination with gem/cis and showed acceptable toxicity;
furthermore, the ErbB family or MAPK pathway alterations were predictive of therapy response [45].
Sorafenib combined with vinflunine in platinum-relapsed mUC patients showed an impressive ORR of
41%, supporting further trials [46]. In summary, RTKs converge on the MAPK and Pi3K/AKT/mTOR
pathways to drive MIBC. Crosstalk between these pathways provides UC cells with mechanisms of
resistance to RTK inhibition. Treatment resistance could be overcome by either the combined inhibition
of multiple RTKs at the same time or interference with the crosstalk between the two pathways in
pre-clinical models. We are looking forward to subsequent clinical trials that evaluate the effect of
FGFR and ErbB family inhibition by, for example, afatinib + erdafitinib administered synchronously or
in short intervals. Likewise, future clinical trials should consider FGFR or ErbB inhibition combined
with Pi3K or mTOR inhibitors.
6. Targeting UC Vascularization with VEGF Inhibitors
Solid tumors depend on adequate blood supply in order to grow and metastasize. In the case of
hypoxia, cells release vascular endothelial growth factor (VEGF), which activates the VEGFR expressed
on vascular endothelial cells, thereby stimulating neovascularization [47]. VEGF or VEGFR have been
targeted in several tumor types to inhibit the formation of new blood vessels, thus impairing tumor
growth [48]. VEGF/VEGFR inhibition is not tumor-specific and there are currently no biomarkers
available to select patients with an increased probability of response to therapy. Thus, VEGF/VEGFR
inhibition can currently be classified as a form of non-personalized, targeted therapy. Several
VEGF/VEGFR-directed therapies have been evaluated in MIBC. Bevacizumab is an antibody that binds
VEGF, preventing the activation of VEGFR. Bevacizumab has been investigated in combination with
gem/cis as a first-line treatment option in mUC and showed an ORR of 72% in a phase II trial [49].
Despite these promising initial results, gem/cis + bevacizumab did not increase the overall survival in a
follow-up phase III trial [50], demonstrating the importance of confirming phase II ORR results in phase
III randomized trials that evaluate overall survival. Ongoing biomarker studies could identify subsets
of patients who benefit from anti-angiogenic therapy. Cabozantinib is a small molecule inhibitor
of VEGFR2 that also inhibits other RTKs (c-MET, AXL, and RET) [51]. Cabozantinib treatment for
mUC is currently under investigation as monotherapy in a third-line setting (NCT01688999). Another
study investigated cabozantinib + nivolumab + ipilimumab and demonstrated a favorable toxicity
profile [52,53]. A phase II trial is currently being performed to evaluate its efficacy (NCT03866382).
The ARCADIA (hARnessing CAbozantinib and Durvalumab Immuno-oncology Association) phase
II trial investigates the efficacy of a cabozantinib + durvalumab combination therapy in patients
with platinum-relapsed mUC (NCT03824691) [54,55]. The safety and tolerability of cabozantinib +
atezolizumab are being investigated in the COSMIC-021 phase Ib trial (NCT03170960) that includes
patients with locally advanced or metastatic UC, among other tumor types [56–58]. Preliminary
results based on the castration-resistant prostate cancer cohort point to a tolerable safety profile for the
treatment combination [59].
The inhibition of neovascularization by blocking VEGF or VEGFR has shown favorable toxicity
profiles that allow for combination therapy with gem/cis or ICI. Anti-VEGF therapy + gem/cis has not
shown a survival benefit despite an impressive ORR of 72% in a phase II trial. Results of clinical trials
that combine VEGFR-inhibition with ICI are currently pending and the value of an anti-VEGF/VEGFR
treatment for mUC is yet unclear. Nonetheless, favorable toxicity profiles support the future evaluation
of anti-VEGF/VEGFR therapy combined with drugs other than gem/cis or ICI.
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7. Promising Targeted Treatment Approach: Antibody–Drug Conjugates
Antibody–drug conjugates (ADCs) are drugs comprised of a monoclonal antibody tethered to a
cytotoxic drug using a linker. ADCs rely on monoclonal antibodies to guide (highly) cytotoxic drugs
to the proximity of target cells, whereupon the drug is released. Ideally, the monoclonal antibody
component targets antigens that are exclusively and homogeneously expressed on cell membranes
of cancer cells [60]. For maximal on-target effects, ADC-targeted antigens are not to be secreted and
are ideally internalized upon ADC binding [61,62]. Drugs tethered using non-cleavable linkers are
only released following a complete proteasomal breakdown of the antibody component and will
remain linked to an amino acid residue derived from the degraded antibody [63]. Cleavable linkers
are designed to release drugs in response to particular extracellular and intracellular environments
(pH, redox potential) or following enzymatic cleavage [63].
The first ADC that received FDA approval for the treatment of mUC patients was enfortumab
vedotin. Enfortumab targets nectin-4 and is tethered to the cytotoxic agent vedotin using a
protease-cleavable linker. FDA approval was based on results of a phase I clinical trial showing a
promising ORR of 42% and a CR of 9% in mUC [64]. Side-effects most often associated with enfortumab
vedotin or other vedotin-based ADCs are fatigue, peripheral neuropathy, rash, and hyperglycemia [65].
Enfortumab vedotin paves the way for other ADCs to be used against MIBC, and ADCs targeting
ErbB family members are currently being evaluated. HER2 overexpression in BC has been targeted
by ADCs, even though the anticancer effect of HER2 inhibition was found to be minimal. Disitamab
vedotin (RC48-ADC) combines the HER2-specific desitamab with vedotin using a protease-cleavable
linker and has shown a promising ORR of 60% in HER2-positive mUC patients that have progressed
on prior platinum-based therapy [66,67]. ADCs based on trastuzumab are also being investigated.
Trastuzumab deruxtecan (DS-8201a) is trastuzumab tethered to the chemotherapeutic agent deruxtecan
via a cleavable peptide linker and is currently being investigated in combination with nivolumab as
a second-line therapy in a phase I trial for patients with HER2-positive metastatic breast cancer or
mUC (NCT03523572). Common grade 3 adverse events associated with trastuzumab deruxtecan are
interstitial lung disease, neutropenia, anemia, or thrombocytopenia. Trastuzumab emtansine (T-DM1)
combines trastuzumab with cytotoxic entamsine and has a non-cleavable linker. Common side effects
are conjunctivitis, dry eyes, and neutropenia. Trastuzumab entamsine was evaluated in a phase I
clinical trial that enrolled patients with multiple tumor types carrying HER2 amplifications but did not
yield any response in the three mUC patients available for analysis [68].
In conclusion, HER2-targeted ADCs, like enfortumab vedotin, are a promising new class of drugs
that exploit HER2 overexpression, irrespective of the anticancer effect of HER2 inhibition.
Patients with EGFR or HER2 overexpression are an interesting population to further investigate
the effect of ADCs. Phase II and phase III clinical trials evaluating EGFR or FGFR-targeted ADCs in
mUC are awaited.
8. Sampling and Trial Setup
Novel anticancer therapies may target rare molecular alterations. The rare occurrence of these
individual driver alterations presents challenges regarding enrolling enough patients with the same
driver alterations and tumor type into clinical trials. Basket trials are designed to overcome this
challenge by enrolling patients with different tumor types but similar molecular alterations. These
trials are based on the assumption that patients with similar driver alterations but different tumor
types will have comparable responses to targeted therapy [69]. The histological background of a
tumor determines how a patient’s cancer cells have evolved and continue to evolve during treatment.
For example, patients with FGFR2/3 alterations are more likely to respond to erdafitinib if they have
urothelial carcinoma or cholangiocarcinoma instead of other tumor types [70].
A major problem with basket trials is the accrual of enough patients with the same tumor type.
This could lead to underpowered evaluations in tumor-type-specific subanalyses. As treatment
responses can differ between different tumor types, there is a risk that basket trials could potentially
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lead to early termination of treatment arms and failure to identify (small) patient populations in
whom biomarker-guided treatments are effective. Umbrella trials do not have this limitation as only
patients with a single tumor type are enrolled. In umbrella trials, patients with the same tumor type
are screened for multiple molecular aberrations and subsequently randomized for either the targeted
therapy or standard of care. Umbrella trials are flexible, which allows for the closing of ineffective
treatment arms and adding treatments without writing a new protocol. The flexibility of umbrella
trials could be embraced to efficiently evaluate the safety profiles of novel drugs. Nonetheless, the
probability that there is a direct therapeutic benefit to participants is low for both trial designs [69].
Clinical trials that evaluate biomarker-guided targeted therapy can be hampered by several hurdles that
need to be overcome. Trials require the accrual of enough patients to allow for subanalyses, acquired
samples should be appropriate for biomarker evaluation, and patient samples should be accessible
for analyses. Problems with patient accrual can be overcome by intensifying the collaboration in
international consortia and designing umbrella trials that include treatment arms for patients without
detected biomarkers.
The accurate biomarker prediction of treatment outcomes requires biomarkers to be assessed using
a patient’s lethal tumor clones. Biomarker accuracy is therefore hampered by tumor heterogeneity. The
mutagenic nature of urothelial cancer gives rise to different tumor subclones that continue to evolve
during a patient’s natural disease course and treatment [71,72]. The mutational variation observed
within a primary tumor appears to explain a minor fraction of the total genetic tumor heterogeneity
observed between primary and metastatic lesions [73,74]. The vast intratumor heterogeneity is
explained by metastatic spread, which is an early event in urothelial cancer evolution and thus few
mutations are shared between primary tumor sites and metastatic lesions [72]. Biomarker assessment on
primary tumors might therefore not be optimal for predicting a targeted treatment response in patients
with mUC. Moreover, the genomic heterogeneity is even greater in patients with multiple primary
tumors, further complicating the use of primary tumor samples for targeted treatment allocation [74].
The sampling bias that arises from a primary tumor that does not correspond with metastatic lesions
could particularly hamper patient selection for anti-FGFR3 therapy, as FGFR3 mutation frequencies
decrease with progression from non-muscle invasive bladder cancer (NMIBC) to MIBC to lymph node
metastasis [12]. To conclude, biomarkers that guide targeted therapy are ideally evaluated in patients’
most lethal tumor clones. Most mUC patients succumb from metastasis, thus biomarker assessment
requires access to metastatic lesions.
Samples from metastatic lesions can be obtained by taking needle biopsies, which is burdensome
and puts patients at risk for complications. Liquid biopsies allow for the evaluation of tumor DNA that
has shed into the circulation. Tumor DNA is continuously shed into the circulation and can be accessed
by drawing blood. The analysis of circulating tumor DNA (ctDNA) using ultra-deep sequencing or
digital droplet PCR allows for the early detection of metastatic relapse and monitoring the treatment
response in a minimally invasive manner [75,76]. Furthermore, actionable molecular alterations, such
as FGFR3 hotspot mutations, have been detected in ctDNA [77,78]. Nonetheless, it remains to be
determined whether a patient’s most burdensome tumor clones can be identified as such by evaluating
the allele frequencies of ctDNA. Ideally, mutations specific to proliferating or metastasizing tumor
clones are indeed represented by greater allele frequencies detected in ctDNA. This would potentially
enable umbrella trials that loop back to renewed biomarker assessment and treatment allocation every
time that a treatment relapse occurs.
9. Future Directions
After years of modest innovation, the clinical practice of treating mUC is now rapidly changing,
driven by the molecular characterization of MIBC. Molecular alterations in RTKs, the MAPK pathway
the PI3K/AKT/mTOR pathway, and chromatin remodelers have been identified as potential candidates
for targeted therapy. Pan-FGFR inhibitors have proven patient benefits and erdafitinib was the first
targeted therapy for mUC that was approved for clinical practice. The clinical efficacy of ErbB family
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inhibition was less promising, but an optimized patient selection and ErbB-directed ADCs are strategies
that could improve treatment outcomes. Enfortumab vedotin is the first-in-class ADC to be introduced
into clinical practice, although phase III trials are awaited to confirm the patient benefits. Lastly,
for future directions, the functions of mutated chromatin remodelers in BC are understudied and their
potential for therapeutic targeting in BC remains to be explored.
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